Matches in SemOpenAlex for { <https://semopenalex.org/work/W2248130959> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2248130959 endingPage "7571" @default.
- W2248130959 startingPage "7571" @default.
- W2248130959 abstract "7571 Background: NEJ002, a phase III trial comparing gefitinib with carboplatin-paclitaxel as the first-line treatment for advanced NSCLC with sensitive EGFR mutations, showed a significant improvement in progression-free survival (PFS) in the gefitinib arm. Although standard schedule of gefitinib was the administration of 250 mg tablet every day, more than half of patients in the gefitinib arm reduced the dose of gefitinib mainly because of toxicities. However, the efficacy of such low-dose (LD) gefitinib has rarely been evaluated. Methods: A post-hoc analysis of the efficacy (response rate and survival) in patients who took gefitinib without any dose reduction during their treatment period and those in patients who received LD gefitinib at any point during the treatment period was performed. Results: Among 114 patients of the first-line gefitinib group in NEJ002, 52 (46%) continued gefitinib without break until their diseases progressed (categorize as group A), and 62 (54%) was reduced their dose of gefitinib (most of them moved into every-2-days schedule) because of some toxicities (same as group B). There was no significant difference of patient characteristics between two groups. Interestingly, PFS of group B seemed to be better than that of group A (median PFS, 301 days in group A versus 351 days in group B; p = 0.450) and overall survival was also similar between the groups (median survival time, 852 days versus 928 days, respectively; p = 0.674). Conclusions: The results suggest that LD gefitinib may be clinically not inferior to standard schedule of gefitinib for NSCLC with sensitive EGFR mutations. Considering the merit in terms of risk-benefit balance, prospective study of LD gefitinib is warranted. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca AstraZeneca" @default.
- W2248130959 created "2016-06-24" @default.
- W2248130959 creator A5007143858 @default.
- W2248130959 creator A5011533142 @default.
- W2248130959 creator A5013199621 @default.
- W2248130959 creator A5017693924 @default.
- W2248130959 creator A5023270271 @default.
- W2248130959 creator A5037355181 @default.
- W2248130959 creator A5044579640 @default.
- W2248130959 creator A5063261090 @default.
- W2248130959 creator A5065197178 @default.
- W2248130959 creator A5077670186 @default.
- W2248130959 date "2010-05-20" @default.
- W2248130959 modified "2023-10-14" @default.
- W2248130959 title "The efficacy of low-dose gefitinib for advanced non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations: A post-hoc analysis from NEJ002." @default.
- W2248130959 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.7571" @default.
- W2248130959 hasPublicationYear "2010" @default.
- W2248130959 type Work @default.
- W2248130959 sameAs 2248130959 @default.
- W2248130959 citedByCount "1" @default.
- W2248130959 crossrefType "journal-article" @default.
- W2248130959 hasAuthorship W2248130959A5007143858 @default.
- W2248130959 hasAuthorship W2248130959A5011533142 @default.
- W2248130959 hasAuthorship W2248130959A5013199621 @default.
- W2248130959 hasAuthorship W2248130959A5017693924 @default.
- W2248130959 hasAuthorship W2248130959A5023270271 @default.
- W2248130959 hasAuthorship W2248130959A5037355181 @default.
- W2248130959 hasAuthorship W2248130959A5044579640 @default.
- W2248130959 hasAuthorship W2248130959A5063261090 @default.
- W2248130959 hasAuthorship W2248130959A5065197178 @default.
- W2248130959 hasAuthorship W2248130959A5077670186 @default.
- W2248130959 hasConcept C121608353 @default.
- W2248130959 hasConcept C126322002 @default.
- W2248130959 hasConcept C143998085 @default.
- W2248130959 hasConcept C168563851 @default.
- W2248130959 hasConcept C203092338 @default.
- W2248130959 hasConcept C2776256026 @default.
- W2248130959 hasConcept C2779438470 @default.
- W2248130959 hasConcept C2780580887 @default.
- W2248130959 hasConcept C67761136 @default.
- W2248130959 hasConcept C71924100 @default.
- W2248130959 hasConceptScore W2248130959C121608353 @default.
- W2248130959 hasConceptScore W2248130959C126322002 @default.
- W2248130959 hasConceptScore W2248130959C143998085 @default.
- W2248130959 hasConceptScore W2248130959C168563851 @default.
- W2248130959 hasConceptScore W2248130959C203092338 @default.
- W2248130959 hasConceptScore W2248130959C2776256026 @default.
- W2248130959 hasConceptScore W2248130959C2779438470 @default.
- W2248130959 hasConceptScore W2248130959C2780580887 @default.
- W2248130959 hasConceptScore W2248130959C67761136 @default.
- W2248130959 hasConceptScore W2248130959C71924100 @default.
- W2248130959 hasIssue "15_suppl" @default.
- W2248130959 hasLocation W22481309591 @default.
- W2248130959 hasOpenAccess W2248130959 @default.
- W2248130959 hasPrimaryLocation W22481309591 @default.
- W2248130959 hasRelatedWork W1602357875 @default.
- W2248130959 hasRelatedWork W1971737397 @default.
- W2248130959 hasRelatedWork W2015910003 @default.
- W2248130959 hasRelatedWork W2017389411 @default.
- W2248130959 hasRelatedWork W2027737109 @default.
- W2248130959 hasRelatedWork W2060263774 @default.
- W2248130959 hasRelatedWork W2186047679 @default.
- W2248130959 hasRelatedWork W2888534976 @default.
- W2248130959 hasRelatedWork W2889523320 @default.
- W2248130959 hasRelatedWork W2978946191 @default.
- W2248130959 hasVolume "28" @default.
- W2248130959 isParatext "false" @default.
- W2248130959 isRetracted "false" @default.
- W2248130959 magId "2248130959" @default.
- W2248130959 workType "article" @default.